Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/31744
Title: | High-dose acetylcysteine in idiopathic pulmonary fibrosis | Authors: | Demedts, M Behr, J Buhl, R Costabel, U Dekhuijzen, R Jansen, HM MacNee, W THOMEER, Michiel Wallaert, B Laurent, F Nicholson, AG Verbeken, EK Verschakelen, J Flower, CDR Capron, F Petruzzelli, S De Vuyst, P van den Bosch, JMM Rodriguez-Becerra, E Corvasce, G Lankhorst, I Sardina, M Montanari, M |
Issue Date: | 2005 | Publisher: | MASSACHUSETTS MEDICAL SOC | Source: | The New England journal of medicine (Print), 353 (21) , p. 2229 -2242 | Abstract: | BACKGROUND Idiopathic pulmonary fibrosis is a chronic progressive disorder with a poor prognosis.METHODS We conducted a double-blind, randomized, placebo-controlled multicenter study that assessed the effectiveness over one year of a high oral dose of acetylcysteine (600 mg three times daily) added to standard therapy with prednisone plus azathioprine. The primary end points were changes between baseline and month 12 in vital capacity and in single-breath carbon monoxide diffusing capacity (DL(sub CO)).RESULTS A total of 182 patients were randomly assigned to treatment (92 to acetylcysteine and 90 to placebo). Of these patients, 155 (80 assigned to acetylcysteine and 75 to placebo) had usual interstitial pneumonia, as confirmed by high-resolution computed tomography and histologic findings reviewed by expert committees, and did not withdraw consent before the start of treatment. Fifty-seven of the 80 patients taking acetylcysteine (71 percent) and 51 of the 75 patients taking placebo (68 percent) completed one year of treatment. Acetylcysteine slowed the deterioration of vital capacity and DL(sub CO): at 12 months, the absolute differences in the change from baseline between patients taking acetylcysteine and those taking placebo were 0.18 liter (95 percent confidence interval, 0.03 to 0.32), or a relative difference of 9 percent, for vital capacity (P=0.02), and 0.75 mmol per minute per kilopascal (95 percent confidence interval, 0.27 to 1.23), or 24 percent, for DL(sub CO) (P=0.003). Mortality during the study was 9 percent among patients taking acetylcysteine and 11 percent among those taking placebo (P=0.69). There were no significant differences in the type or severity of adverse events between patients taking acetylcysteine and those taking placebo, except for a significantly lower rate of myelotoxic effects in the group taking acetylcysteine (P=0.03).CONCLUSIONS Therapy with acetylcysteine at a dose of 600 mg three times daily, added to prednisone and azathioprine, preserves vital capacity and DL(sub CO) in patients with idiopathic pulmonary fibrosis better than does standard therapy alone. | Document URI: | http://hdl.handle.net/1942/31744 | ISSN: | 0028-4793 | e-ISSN: | 1533-4406 | DOI: | 10.1056/NEJMoa042976 | ISI #: | WOS:000233434500006 | Rights: | 2005 Massachusetts Medical Society. All rights reserved. | Category: | A1 | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
45651_207328y.pdf Restricted Access | Published version | 220.24 kB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
782
checked on Sep 3, 2020
WEB OF SCIENCETM
Citations
723
checked on Aug 3, 2024
Page view(s)
36
checked on Sep 7, 2022
Download(s)
4
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.